







































Cross-species models of attention-deficit/hyperactivity
disorder and autism spectrum disorder: lessons from
CNTNAP2, ADGRL3, and PARK2
Elisa Dalla Vecchiaa,*, Niall Mortimerb,d,e,*, Viola S. Palladinoc,*,
Sarah Kittel-Schneiderc, Klaus-Peter Leschb,f,g, Andreas Reifc,
Annette Schenckh and William H.J. Nortona
Animal and cellular models are essential tools for all
areas of biological research including neuroscience.
Model systems can also be used to investigate the
pathophysiology of psychiatric disorders such as
attention-deficit/hyperactivity disorder (ADHD) and
autism spectrum disorder (ASD). In this review, we
provide a summary of animal and cellular models
for three genes linked to ADHD and ASD in human
patients – CNTNAP2, ADGRL3, and PARK2. We also
highlight the strengths and weaknesses of each
model system. By bringing together behavioral and
neurobiological data, we demonstrate how a cross-
species approach can provide integrated insights
into gene function and the pathogenesis of ADHD
and ASD. The knowledge gained from transgenic
models will be essential to discover and validate new
treatment targets for these disorders. Psychiatr Genet
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Introduction
Psychiatric disorders
Psychiatric disorders can affect any aspect of mental health,
including cognition, emotionality, and sociability. They are a
leading cause of disability worldwide and represent a sig-
nificant economic burden to the society (Bloom et al., 2012;
Vigo et al., 2016). The aim of this research using animal and
cellular models is to better understand the neurobiology
of psychiatric disorders to develop new treatments for the
individuals that experience them. In this review, we dis-
cussed models for two common overlapping psychiatric
disorders: attention-deficit/hyperactivity disorder (ADHD)
and autism spectrum disorder (ASD).
Attention-deficit/hyperactivity disorder and autism
spectrum disorder
ADHD and ASD are two of the most widely studied
neurodevelopmental disorders. According to the Diagnostic
and Statistical Manual of Mental Disorders, 5th ed. (DSM-5),
ADHD is a clinically heterogeneous disorder characterized
by inattention, hyperactivity, and increased impulsivity
(American Psychiatric Association, 2013). Approximately
2–10% of school-age children are affected by ADHD
(Hawi et al., 2015), and males are more likely to be affected
than females (Polanczyk et al., 2007; Nussbaum, 2012).
Despite traditionally being regarded as a childhood disorder,
a number of longitudinal-based and population-based epi-
demiological studies have identified an adult form of ADHD
(Franke et al., 2012, 2018). ASD is a group of neurodeve-
lopmental disorders characterized by impairments in learn-
ing, sensory filtering, communication, and social interactions
together with restricted, repetitive, and stereotypical beha-
viors and interests. The prevalence of ASD in the population
is estimated at ~1%, with three to four times as many males
as females affected (Baird et al., 2006). There are currently no
objective laboratory-based tests to diagnose ADHD or ASD.
The latest version of theDSM acknowledges the high rate of
comorbidity for ASD and ADHD, allowing their simulta-
neous diagnosis for the first time (American Psychiatric
Association, 2013). The symptoms of ADHD and ASD often
co-exist. Overall, 20–50% of children with ADHD also meet
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the criteria for ASD (Rommelse et al., 2011). Several studies
have shown social deficits, peer relationship deficits, and
empathy problems in children with ADHD, and the DSM-5
allows a comorbid diagnosis of both disorders. Although
ADHD and ASD comorbidity has mainly been studied in
children, there is also evidence that it occurs in adults
(Hartman et al., 2016). The drugs most commonly used to
treat ADHD are stimulants such as methylphenidate (MPH).
Although effective in controlling some symptoms, MPH
treatment shows a large degree of variability across patients
(Wolraich and Doffing, 2004). There are currently no phar-
macological treatments for the core symptoms of ASD.
Behavioral therapy can improve the quality of life for patients
with ASD, and pharmacological treatments may reduce
secondary symptoms such as hyperactivity (LeClerc and
Easley, 2015).
Genetic and environmental factors for autism spectrum
disorder and attention-deficit/hyperactivity disorder
A combination of both environmental factors and genetic
variants are known to influence the development and
expression of ADHD and ASD (Sánchez‐Mora et al.,
2015; Sjaarda et al., 2017). Meta-analysis of multiple
large-scale twin studies estimated the heritability of
childhood and adolescent ADHD at between 0.7 and 0.8
(Nikolas and Burt, 2010). The heritability of adult
ADHD is reported to be lower, at between 0.3 and 0.4,
although this may be an underestimation owing to the
self-rating system commonly used in these studies
(Franke et al., 2018). The true heritability could be as
high as 0.7–0.8 (Brikell et al., 2015; Tick et al., 2015). ASD
heritability estimates are similarly high at 0.64–0.91 (Tick
et al., 2015). Familial co-aggregation of ADHD and ASD
is strongly indicative of an overlap in genetic factors
across disorders (Ghirardi et al., 2018). Furthermore, a
number of studies have identified genes that are asso-
ciated with both ADHD and ASD, including contactin-
associated protein-like 2 (CNTNAP2) (Strauss et al., 2006;
Elia et al., 2010; Poot et al., 2010; Rodenas-Cuadrado
et al., 2014).
The genetic basis of ADHD and ASD can be explained
by the common disease common variant and common
disease rare variant (CDRV) hypotheses (Hawi et al.,
2015). However, there is a growing recognition that most
individuals with ADHD or ASD carry both common and
rare variants. The common disease common variant
hypothesis focuses on multiple common polymorphisms,
with a frequency greater than 5%. Each polymorphism
has a low level of penetrance, but when combined they
can increase the risk of developing ADHD or ASD. This
hypothesis has formed the basis of molecular genetic
research over the past two decades starting with the
investigation of preselected candidate genes in relatively
small studies (Li et al., 2014). With the advent of high-
throughput genetic screening, researchers could conduct
hypothesis-free experiments in large samples of patients
and controls. These genome-wide association studies
have identified a number of polymorphisms, which con-
fer a slightly increased risk of developing a psychiatric
disorder. Common variants have been estimated to
explain 22% of ADHD heritability and 32% of ASD
heritability (Autism Spectrum Disorders Working Group
of The Psychiatric Genomics Consortium, 2017;
Demontis et al., 2017). Some of the missing heritability
can be explained by the CDRV hypothesis. ADHD and
ASD might be caused by genetic variants that are rare in
the overall population but have high penetrance in
individuals. Rare variants such as monogenic or chro-
mosomal abnormalities are a common cause of syndromic
ASD, and in some cases, these abnormalities can be
identified by genetic testing (Fernandez and Scherer,
2017). Nonsyndromic ASD might also be caused by
monogenic mutations in genes such as Neurexin 1
(NXRN1) and SH3 and multiple ankyrin repeat domains
(SHANK3) (Caglayan, 2010). Another type of rare variant
that has been intensely studied is copy-number variations
(CNVs). CNVs are chromosomal deletions or duplica-
tions that can span several megabases and which alter
normal gene expression (Redon et al., 2006). The rele-
vance of CNVs to a particular phenotype can be linked to
their position, length, and heterozygosity. There is
increasing evidence that CNVs play a role in the patho-
genesis of several neurodevelopmental disorders, and it
has been demonstrated that patients with ASD have a
higher burden of CNVs compared with healthy controls
(Shishido et al., 2013). Testing for CNVs in patients with
ADHD has identified a number of genes that had pre-
viously been implicated in ASD, demonstrating the
shared genetic risk for these disorders (Lionel et al.,
2011). Other studies have also reported a greater burden
of CNVs in patients with ADHD without reporting
comorbidity with ASD (Williams et al., 2010, 2012).
These CNVs include the parkin 2 (Park2) and neuro-
peptide Y loci (Lesch et al., 2011; Jarick et al., 2014) and
genes in the metabotropic glutamate receptor family
(Elia et al., 2012). There is some evidence that CNVs
may contribute to adult ADHD as well (Ramos-Quiroga
et al., 2014), although different genes may be affected.
The growing consensus among researchers is that ASD
and ADHD are caused by a number of synergistic factors
including CNVs, rare variants, and common polymorph-
isms (Kiser et al., 2015).
Environmental factors including epigenetic modifications
have also been linked to these disorders. The prenatal and
perinatal stages appear to be particularly susceptible to
environmental stimuli. Both premature birth and maternal
smoking during pregnancy have been linked to an
increased risk of developing ADHD (Halmøy et al., 2012;
Zhu et al., 2014). However, when genetic and familial
confounders are included, the strength of these associa-
tions decreases, calling into question any causal relation-
ship (Sciberras et al., 2017). A further meta-analysis of
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15 studies failed to find an association between maternal
smoking and ASD (Rosen et al., 2014). Even within the
prenatal period, the effect of environmental stimuli
depends upon the trimester during which exposure occurs.
Exposure to antidepressants during the second and third
trimesters has been associated with an increased risk of
developing ASD (Boukhris et al., 2016). However, a cohort
study of more than 1.5 million Swedish children failed to
find an association between maternal antidepressant use
during the first trimester and risk of either disease (Sujan
et al., 2017). In the perinatal period, strong associations
between ASD and birth complications leading to trauma,
ischemia or hypoxia have been reported (Modabbernia
et al., 2017). Both prenatal and postnatal exposures to
abnormal levels of metal toxicants and essential elements
have been associated with ASD (Arora et al., 2017). After
the antenatal period, a number of early life factors have
been linked to these disorders. These include an asso-
ciation between maternal anxiety, depression, and ADHD
in 3-year olds (Meadows et al., 2007) and increased
parental age and ASD risk (Wu et al., 2016). However,
whether causality between environmental factors and
neurodevelopmental disorders exists can be hard to
determine, and further research, including the use of
animal models, is required to investigate this issue.
Cross-species models
The use of animal and cellular models to understand the
pathogenesis of human disease and develop treatments
has greatly contributed to our understanding of several
psychiatric disorders. These models are suitable for large-
scale trials that can be translated into human clinical
research (Crawley, 2012; van der Voet et al., 2014; Falk et al.,
2016; Kim et al., 2016; Ardhanareeswaran et al., 2017).
Mouse (Mus musculus)
The mouse is the most commonly used model organism
in biomedicine. Their short generation time, small size,
and social nature allow a large number of animals to be
housed in a small facility. The sequencing of the mouse
genome combined with the tools to manipulate it in a
targeted manner has revolutionized biomedical research
(Hara and Takada, 2017). As mice and humans are very
similar genetically (∼99% homology), it is possible to
investigate genes identified in human studies in mice.
Following genetic manipulation, a combination of highly
standardized behavioral and neurobiological techniques
can be performed. This can provide insights into how
polymorphisms or mutations can lead to the pathology of
psychiatric disorders (Arguello and Gogos, 2006). Of
particular relevance to psychiatric disorders, mice exhibit
a range of complex behaviors including reciprocal social
interactions (McCammon and Sive, 2015). Mice are often
the first step in testing a new treatment for toxicity and
efficacy (Vandamme, 2014).
Zebrafish (Danio rerio)
The zebrafish is an emerging model organism for bio-
medical research thanks to their short generation time,
small size, and genetic tractability. Zebrafish are parti-
cularly useful for developmental and live imaging stu-
dies, as they develop externally and are transparent at
larval stages. Almost 70% of human genes have at least
one zebrafish orthologue (Howe et al., 2013). Transient
knockdown of genes in zebrafish was initially achieved
by injecting morpholino oligonucleotides (Blum et al.,
2015). Recently, stable mutant lines have been created
using CRISPR/Cas9 genome editing (Schmid and Haass,
2013). However, modelling human disorders in zebrafish
is complicated by an additional whole-genome duplica-
tion which occurred ~ 440 million years ago (Amores et al.,
2011). Despite this issue, zebrafish are uniquely suited
for high-throughput pharmacological studies, as larvae
can be generated in large numbers and drugs can be
applied by dilution in the embryo medium (Rihel et al.,
2010; Norton, 2013; Gutiérrez et al., 2018). Zebrafish can be
used to study ADHD and ASD thanks to their stereotypical
behavior and social interactions. It is also possible to test
cognitive deficits in this species. Spatial working memory
can be measured in the habituation to novelty test, and
various forms of learning can be assessed using robust
behavioral paradigms (Stewart et al., 2014).
Fruit fly (Drosophila melanogaster)
The fruit fly is a widely used model system that has
greatly contributed to neuroscience research (Bier, 2005).
Fruit flies are small and easy to maintain with a very short
generation time, which allows large-scale low-cost
experiments. Although the fruit fly brain is relatively
small, it is still complex enough to model some aspects of
psychiatric disorders (Bellen et al., 2010). Signalling
pathways and regulatory molecular networks are also well
conserved. Overall, 75% of human disease genes have
related sequences in the fly (Bier, 2005). Furthermore,
the temporally inducible UAS-GAL4 system can be used
to target specific cell types in Drosophila (Brand and
Perrimon, 1993). When this system is coupled to the
expression of RNA interference molecules, it allows
reversible genetic manipulation. Transgenic flies can also
be generated using the P-element system (Rubin and
Spradling, 1982), and CRISPR/CAS9 technology now
permits ubiquitous or tissue-specific genome editing
(Port et al., 2014). Drosophila display a behavioral reper-
toire that varies from simple aggregation to more complex
behaviors such as aggression and courtship (O’Kane,
2011). Therefore, even though the nervous system and
social behavior of Drosophila are not that similar to ver-
tebrates, the fruit fly presents a valuable model to
characterize mechanisms underlying disease-related
behaviors (van Alphen and van Swinderen, 2013; van
der Voet et al., 2014).
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Human induced pluripotent stem cells
The recent development and improvement of human
induced pluripotent stem cell (hiPSC) technology per-
mits the conversion of tissue into pluripotent cells that
can be redifferentiated into neurons in a noninvasive and
ethical manner (Takahashi et al., 2007). This technique
offers the possibility to use a range of different samples
including skin biopsies, urine samples, and hair follicles.
A great advantage of this method is that the genetic
makeup of patients is included in the experimental
model rather than investigating the influence of single
genes. This may be particularly important for multi-
factorial diseases such as ADHD and ASD. hiPSCs also
represent an innovative tool for large-scale drug screen-
ing. Moreover, neurons obtained from hiPSCs can be
cultured in two dimensions, for single neuron analysis,
or in three-dimensional aggregates (brain organoids),
allowing evaluation of network-level effects (Falk et al.,
2016; Frega et al., 2017; Prytkova and Brennand, 2017). In
recent years, hiPSCs have been used as a tool to model
psychiatric disorders such as ASD, ADHD, bipolar dis-
order, Schizophrenia, and the response to lithium at a
cellular level (Prilutsky et al., 2014; Ardhanareeswaran
et al., 2015; Lim et al., 2015; Soliman et al., 2017; Hoffman
et al., 2018; Jansch et al., 2018).
A single model cannot capture all the traits of a complex
brain disorder such as ASD and ADHD. As specific
behavioral and neurobiological features may be more
easily studied in certain organisms, a comparative study
across models should be performed whenever possible
(Stewart et al., 2015; Wong and Josselyn, 2016).
Contactin-associated protein-like 2, adhesion G protein-
coupled receptor L3, and parkin 2
Human genetic studies have identified a large number of
genes linked to ADHD and ASD. There are currently
359 genes implicated in ADHD according to the
ADHDGene database, whereas 1007 genes are included
in the SFARI Gene database for ASD (Zhang et al., 2011;
Abrahams et al., 2013). In this review, we have chosen to
focus on three candidate genes for ADHD and ASD:
CNTNAP2, adhesion G protein-coupled receptor L3
(ADGRL3), and PARK2. As well as being involved in
diverse biological processes, the types of variants linking
these genes to disease are also different. CNTNAP2 was
initially implicated in ASD through a recessive single
base pair deletion in the coding region. In contrast, the
association between ADGRL3 and ADHD comes from
noncoding single nucleotide polymorphisms (SNPs),
which may affect gene expression levels (Strauss et al.,
2006; Martinez et al., 2016). Larger scale CNVs in PARK2
are associated with ASD (Glessner et al., 2009; Scheuerle
and Wilson, 2011). CNTNAP2 and PARK2 are primarily
implicated in ASD but have also been linked with
ADHD. ADGRL3 is linked with ADHD and substance
use disorders (SUD), but there is currently no strong
connection to ASD (Gau et al., 2012). Together this
review provides an overview of how genes with different
biological functions can be studied in model systems to
understand the comorbidity of ADHD and ASD.
Contactin-associated protein-like 2
Biological and molecular description
CNTNAP2 is one of the largest human genes. It spans
2.3Mb and is located in chromosomal region 7q35.
CNTNAP2 encodes the neuronal transmembrane protein
CASPR2, a member of the neurexin (NRXN) super-
family of single-pass transmembrane proteins. CASPR2 is
composed of 1331 amino-acid residues organized into
eight extracellular domains, two C-terminal intracellular
domains, and one transmembrane domain (Poot, 2015).
The intracellular domain of CASPR2 may be involved in
protein–protein interactions, whereas the extracellular
domains mediate cell–cell interactions and bind ligands,
receptors, and extracellular matrix components (Poot,
2015; Baig et al., 2017). CNTNAP2 forms a neuron–glia
adhesion complex with contactin 2 that localizes voltage-
gated potassium channels to the juxtaparanodal region of
myelinated axons (Poliak et al., 1999, 2003). The first link
between CNTNAP2 and ASD was a recessive mutation
found in an Amish family affected by a syndromic form of
ASD called cortical dysplasia-focal epilepsy syndrome
(Strauss et al., 2006). Several more studies have provided
convergent evidence that rare and common variations in
CNTNAP2 confer risk for ASD-related endophenotypes
such as developmental language disorders and ASD itself
(Peñagarikano and Geschwind, 2012). CNTNAP2 has
also been linked to schizophrenia, epilepsy, intellectual dis-
ability, learning disability, and ADHD (Rodenas-Cuadrado
et al., 2014). However, most studies have focused on the role
of CNTNAP2 in ASD.
In this review, we have chosen to focus on these three
candidate genes because they are linked to either ADHD
(ADGRL3), ASD (CNTNAP2), or both disorders (PARK2).
Each gene has been modelled in a number of different
species, making these candidates ideal to demonstrate
the power of comparative studies to help translate find-
ings to human patients.
Models
Mouse
The first Cntnap2 mutant mouse was generated in 2003
(Poliak et al., 2003). After the identification of CNTNAP2
as a candidate gene for ASD, the original strain was
backcrossed onto the C57BL/6J background, which is
more suitable for behavioral characterization (Crawley
et al., 1997; Penagarikano et al., 2011). Cntnap2 KO mice
display deficits in core behavioral features of ASD: social
deficits, restrictive and repetitive behaviors, and reduced
vocal communication (Table 1). When compared with
wild-type littermates, these mice appear normal, and
there are no differences in growth rate and final size.
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Interestingly, after six months, Cntnap2− /− mice develop
epileptic seizures and their electroencephalogram has an
abnormal pattern during slow wave sleep. In addition,
knockout mice are hyperactive (Penagarikano et al.,
2011). Cntnap2− /− mice show neuronal migration
abnormalities that reveal the fundamental role of this
gene in cortical projection neuron migration (Penagarikano
et al., 2011). Interestingly, it has been found that Cntnap2− /−
mice display a reduced number of GABAergic interneurons
(Penagarikano et al., 2011). Pharmacological treatment with
risperidone rescued the stereotypic behavior of Cntnap2− /−
mice, whereas social deficits were unaffected, similar to
the pattern of improvements seen in human patients
(Penagarikano et al., 2011). Overall, this model recapitu-
lates certain features of patients with CNTNAP2mutations,
and this is one of the best studied genes for this disorder
(Poot, 2015).
Zebrafish
A zebrafish cntnap2 mutant model was recently created
(Table 2). Cntnap2a− /− and cntnap2b− /− double mutants
(cntnap2ab) harbor homozygous loss-of-function muta-
tions in both genes resulting in a complete loss of the
protein (Hoffman et al., 2016). Hoffman et al. (2016)
analyzed excitatory and inhibitory neuron populations in
cntnap2ab during early development, as an imbalance in
inhibitory and excitatory signalling could be involved in
ASD (Rubenstein and Merzenich, 2003). They observed
that mutants have a smaller head than wild type.
Moreover, mutants show a decrease in GABAergic cell
count; however, there were no prominent deficits in
glutamatergic neurons (Hoffman et al., 2016). Loss of
inhibitory neurons can increase seizure susceptibility
(Cobos et al., 2005). Zebrafish cntnap2ab mutants are
more sensitive to drug-induced seizures and show night-
time hyperactivity, another phenotype linked to the
imbalance between excitatory and inhibitory neuro-
transmission. The night-time hyperactivity phenotype
can be rescued by estrogens (Hoffman et al., 2016). This
finding has reinforced the use of whole organism drug
screening as an effective system to identify compounds
that can be developed into pharmaceutical treatments.
Fruit fly
CNTNAP2 and NRXN1 are members of the neurexin
superfamily. SNPs and CNVs in both genes have been
associated with disorders including ASD. Zweier et al.
(2009) have used Drosophila to examine a common synaptic
link between these two genes and neuropsychiatric dis-
orders (Table 3). This group studied both Nrx-I and Nrx-IV,
the Drosophila orthologs of NRXN1 and CNTNAP2.
Knockdown (KO) of Nrx-IV, either ubiquitously or only in
neurons, led to late embryonic lethality. Immunostaining of
Nrx-IV KO embryos showed an overall reduction in staining
for the presynaptic protein bruchpilot that maintains the
structural integrity of synaptic active zones (Wagh et al.,
2006). They also found a dosage-dependent increase of
bruchpilot staining whenNrx-IVwas overexpressed in larval
neurons. bruchpilot and Nrx-I colocalize at presynaptic
active zones (Li et al., 2007). In conclusion, CNTNAP2 and
NRXN1 may be involved in a common synaptic mechan-
ism, contributing to the etiology of neurodevelopmental
disorders together with bruchpilot (Zweier et al., 2009).
Further studies are required to determinate the mechanism
by which Nrx-I and Nrx-IV control bruchpilot levels.
Human induced pluripotent stem cells
hiPSCs carrying a heterozygous deletion in CNTNAP2
have been generated to characterize the associated
molecular and cellular phenotypes (Table 4). However,
they were derived from a female proband who met the
DSM-IV criteria for schizo-affective disorder, not ASD or
ADHD. hiPSCs were also generated from both parents as
well as five unrelated healthy controls (Lee et al., 2015).
Neural migration was quantified using a neurosphere assay.
Interestingly, hiPSC neural progenitor cells derived from the
heterozygous CNTNAP2 schizo-affective patient showed sig-
nificantly reduced neural migration relative to controls (Lee
et al., 2015). This phenotype is consistent with the neuronal
migration abnormalities observed in the Cntnap2− /− mouse
model of ASD (Penagarikano et al., 2011). Global gene
expression and neuronal activity were analyzed in the same
cohort. HiPSC-derived neurons from individuals carrying the
heterozygous CNTNAP2 deletion show altered neuronal
activity and differential expression of genes involved in
synaptic transmission (Flaherty et al., 2017).
Adhesion G protein-coupled receptor L3
Biological and molecular description
The latrophilin family of proteins was initially discovered
owing their ability to bind α-latrotoxin, a component of
black widow spider venom (Davletov et al., 1996). The
ADGRL3 (previously known as LPHN3) is of particular
interest in relation to neurodevelopmental disorders.
Multiple polymorphisms in ADGRL3 have been linked to
an increased risk of ADHD and SUD (Arcos-Burgos et al.,
2010; Ribasés et al., 2010). ADGRL3 forms a trimeric
complex with FLRT3 and UNC5, which supports
transcellular adhesion and glutamatergic synapse devel-
opment (Jackson et al., 2015). The identification of
ADGRL3 in human genetic studies, coupled with its
putative roles in neuronal migration and synapse devel-
opment, provides strong support for ADGRL3 poly-
morphisms in the development of ADHD (O’Sullivan
et al., 2014). The lack of naturally occurring coding var-
iants in humans greatly limits our ability to investigate
ADGRL3 (Orsini et al., 2016). Coding variants may not
affect the genes that they are located in, but may rather
have effects elsewhere in the genome. However, there is
functional evidence that the noncoding variant rs2271338
affects ADGRL3 expression, further linking this gene to
ADHD (Martinez et al., 2016).
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Table 2 Fish models
Mutation General appereance Neuronal activity Histologycal analyses Locomotor activity
Excitatory/inibithory
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Table 4 Human induced pluripotent stem cells
Mutation Neural differentiation
Exon, allele and gene specific
expression Biochemical features References
CNTNAP2 Four patient-derived lines: (patient carrying a 289 kb
heterozygous deletion – exons 14–15)
hiPSC neural progenitor cells
Two independents hiPSC-derived neurons
hiPSC-derived oligodendrocyte precursor cells
↓ Neural migration
altered neuronal activity
Differential expression of genes
involved in synaptic transmission
↓ Expression of 14–15 exon
↑ Expression of 23-24 exon
↑ Expression of the mutant allele
– Lee et al. (2015),
Flaherty et al. (2017)
PARK2 Two patient-derived lines:
Heterozygous deletion exon 3 and exon 5
Homozygous deletion exon 3
↓ Neuronal processes complexity (length,
number of terminals, branch points)
↓ Microtubule stability
– ↑ Spontaneous DA release
↓ DA uptake
↓ DAT binding sites
↑ ROS (by increasing MAO
transcripts)
Jiang et al. (2012),
Ren et al. (2015)
Four patient-derived lines:
Compound heterozygous deletion exon 3 and R42P




Two isogenic lines (PARK− /− , PARKw+ /−)
↓ DA differentiation – ↓ Mitochondrial volume fraction
Mitochondrial ultrastructure
abnormalities (PARK− /− line)
Shaltouki et al. (2015)
Two patient-derived lines:
homozygous deletion exon 2–4
Homozygous deletion exon 6 and 7
– – ↑ Oxidative stress and ROS
↑ Nrf2 pathway
Abnormal mitochondrial morphology
SNCA accumulation in one line
↓Mitophagy
Imaizumi et al. (2012),
Suzuki et al. (2017)
Three patient-derived lines:
compound heterozygous deletion exon 7 and
c.1072delT
Compound heterozygous deletion exon 1 deletion
and c.924C> T
Homozygous deletion c.1072delT
– – ↓ Complex I activity
↑ Mitochondrial branching
Zanon et al. (2017)
One patient-derived line:
Heterozygous deletion exon 5
– – ↓ Proteasome activity
↓ Antioxidative pathways
Chang et al. (2016)





















ADGRL3− /− mice displayed hyperactivity in the open-
field test, (Table 1) but no significant genotype differ-
ences were observed in the amount of time spent in the
center of the open field, a common test for anxiety.
ADGRL3 null mice also displayed a heightened loco-
motor response to cocaine. A differential response to
cocaine is of interest because of the link between
ADGRL3 polymorphisms and SUD (Arcos-Burgos et al.,
2012). In a food reward paradigm, ADGRL3− /− mice
displayed increased levels of motivation to work for food,
whereas motor coordination was unaffected in the rotarod
test. In the Porsolt swim test, ADGRL3− /− mice spent
more time swimming and had increased latency to
immobility, possibly owing to reduced depressive beha-
vior or hyperactivity. Whole brains of ADGRL3− /− and
wild-type P0 pups were used to quantify candidate gene
expression by qPCR. The genes chosen were involved in
neuronal differentiation and survival as well as dopami-
nergic (DA) and serotonergic neurotransmission. The
following genes were differentially expressed in ADGRL3− /− :
serotonin transporter (SLC6A4), serotonin 2C receptor
(5-Htr2c), dopamine transporter (SLC6A3), dopamine receptor
D4 (Drd4), neural cell adhesion molecule 1 (Ncam1), nuclear
receptor subfamily 4 group A member 2 (Nr4a2), and tyrosine
hydroxylase (Th). High-pressure liquid chromatography
also revealed an increased level of dopamine and 5-HT
in ADGRL3− /− mice (Wallis et al., 2012). Transcriptomic
analysis was performed on the prefrontal cortex, striatum, and
hippocampus of ADGRL3− /− and control mice at 4 days,
28 days, and 6 months. Collapsing the RNA-sequencing
results across brain regions and time points identified 11 genes
that are differentially expressed in ADGRL3− /− mice.
Two of these genes (Pcdhgb8, upregulated and Pcdhb9,
downregulated) are members of the protocadherin family
of calcium-dependent cell–cell adhesion molecules (Orsini
et al., 2016), which have been linked to ADHD and ASD
(Rivero et al., 2015). Independent analysis of brain regions
and time points revealed a large number of differentially
expressed genes including overexpression of Htr2c
[5-hydroxytryptamine (serotonin) receptor 2c] in the
cortex and SLC6A3 (dopamine transporter) in the hippo-
campus of 6-month old ADGRL3− /− mice. Gene set
analysis did not find a statistically significant enrichment
of gene sets following adjustment for multiple testing.
However, a number of the most enriched pathways were
relevant to ADHD and SUD, including synaptic vesicle
cycle, DA synapse, glutamatergic synapse, neurotrophin
signalling pathway, and both amphetamine and nicotine
addiction.
Zebrafish
Zebrafish have two paralogues of human ADGRL3: adgrl3.1
and adgrl3.2. adgrl3.1 shows a more specific expression
pattern during embryonic development. adgrl3.1 morphant
larvae displayed hyperactivity under both light and dark
conditions at 6 days after fertilization (Table 2). The
increased distance swum was because of greater accelera-
tion and average speed throughout the trial (Lange et al.,
2012). In most patients with ADHD, MPH administration
results in a reduction in hyperactivity (Ramos-Quiroga et al.,
2009). MPH decreased hyperactivity in adgrl3.1 morphant
fish but not in controls. The total distance swam was
reduced by decreasing the average speed. Application of
another ADHD treatment drug, the selective noradrenaline
reuptake inhibitor atomoxetine, reduced the total distance
swam by adgrl3.1 morphant zebrafish by increasing the
resting time. The number of DA neurons in the posterior
tuberculum of adgrl3.1 morphants was reduced at 3 and
6 days after fertilization. Subregions of the posterior tuber-
culum were also disorganised (Lange et al., 2012).
Projectome analysis has indicated a functional correlation
between the posterior tuberculum and the mammalian A11
group of DA neurons (Tay et al., 2011). Administration of
DA receptor agonists and antagonists showed that adgrl3.1
MO larvae are hyposensitive to DA manipulation compared
with adgrl3.1 CO. A possible explanation for this hypo-
sensitivity is that there could be a heightened level of DA
in the synaptic cleft of adgrl3.1 morphants, which might
desensitize both DA-1 and DA-2 like receptors. A heigh-
tened level of DA might also explain the hyperactivity
observed in these animals (Lange et al., 2018). An evolu-
tionarily conserved enhancer for adgrl3.1 has been used to
express green fluorescent protein in zebrafish. This
enhancer was sufficient to produce an expression pattern
similar to endogenous adgrl3.1 in the fore, mid, and hind-
brain but not in the telencephalon and retina (Martinez
et al., 2016).
Fruit fly
The Drosophila orthologue of ADGRL3 is known as latro-
philin. Locomotion activity and sleep have been assessed in
latrophilin KO flies using the Drosophila Activity Monitor
(Table 3). Latrophilin KO flies were found to have heigh-
tened locomotor activity and reduced sleep, particularly
during the 12-h night period. Testing in constant darkness
showed that this hyperactive phenotype was light depen-
dent. As light can buffer the wake-promoting effect of DA
(Shang et al., 2011), the presence of a light-sensitive phe-
notype hints at a disruption of the DAergic system.
However, the number and position of DA neurons is nor-
mal in latrophilin flies, suggesting that impairment of the
DA system may result from changes in downstream sig-
nalling.Drosophilawith a pan-neuronal KO of the dopamine
transporter (DAT) gene displayed a similar light-sensitive
hyperactive phenotype. Furthermore, application of MPH
normalized the locomotor and sleep phenotype of latro-
philin flies, further linking this gene to DA signalling (van
der Voet et al., 2015).
Cellular models
Although no hiPSCs-containing ADGRL3 polymorphisms are
currently available, a number of conventional cellular models
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have been used to study this gene. A family-based genetic
analysis of 838 individuals identified six evolutionary con-
served regions (ECRs) in the ADGRL3 genomic region that
contained SNPs or haplotypes linked to ADHD (Martinez
et al., 2016). ECR 37 and 47 were the only regions found to
drive luciferase expression. The ECR 37 risk variant did not
affect luciferase levels whereas the ECR 47 risk haplotype
reduced luciferase activity by ~40% in both B35 neuro-
blastoma and U87 astrocytoma cell lines. Transcription factor
binding motif analysis of ECR 47 showed an over-
representation of transcription factors associated with brain
function. Electromobility shift assays showed that the
rs2271338 SNP in ECR 47 prevented binding of the Yin
Yang 1 (YY1) transcription factor. However, YY1 interfering
small RNA molecules did not reduce ADGRL3 expression
in SH-SY5Y neuroblastoma cells, perhaps because of an
inability to model this complex interaction outside of its
native system. Expression quantitative trait loci analysis of
post-mortem human brain tissue has linked the rs2271338
AA risk genotype allele to decreased thalamic expression of
ADGRL3 (Martinez et al., 2016).
PARK2
Biological and molecular descriptions
Mutations in PARK2 were first discovered in a small
percentage of patients with Parkinson’s disease (Lücking
et al., 2000). Subsequent whole-genome studies have
linked PARK2 CNVs with Han Chinese children with
ASD (Yin et al., 2016) and European populations
(Glessner et al., 2009; Scheuerle and Wilson, 2011). CNVs
within the PARK2 locus have also been found among
ADHD patient cohorts (Jarick et al., 2012).
PARK2, also known as PRKN, codes for an E3 ubiquitin
ligase previously called Parkin. One of the most studied
partners of PARK2 is the serine/threonine protein kinase
PINK1. Acting together, PARK2 and PINK1 constitute an
internal sensor system for disparate perturbations to cellular
homeostasis (Pickrell and Youle, 2015). In fact, different
stimuli can lead to PINK1 accumulation on the outer
mitochondrial membrane where it can recruit and activate
cytosolic PARK2. PARK2 can then target several mito-
chondrial proteins for degradation (Hang et al., 2015). The
interaction between PINK1 and PARK2 plays a pivotal role
in mitochondria dynamics and quality control, regulating
processes such as mitophagy, fusion and fission, biogenesis,
and transport (Scarffe et al., 2014). PARK2 is also linked to
apoptotic pathways and could exert a proapoptotic or anti-
apoptotic effect in a stressor-dependent and environmental-
dependent manner (da Costa et al., 2009; Müller-Rischart
et al., 2013; Hollville et al., 2014; Zhang et al., 2014).
PARK2 shows high amino-acid sequence conservation
across species, suggesting that it has an evolutionarily
conserved function (Pienaar et al., 2010). Orthologues of
this gene have been found in most of the model organ-
isms used in translational research, permitting the
molecular function of this gene to be studied in different
systems (Pienaar et al., 2010).
Models
Mouse
Surprisingly, Park2− /− mice do not represent a robust
model for Parkinson’s disease (Perez and Palmiter, 2005),
but phenotypic characterization of these animals can be
used to investigate whether there is a link to neurode-
velopmental disorders like ADHD and ASD (Table 1).
Park2− /− mice did not show impairment of general
activity, coordination, and gait performance (Goldberg
et al., 2003; Perez and Palmiter, 2005; Rial et al., 2014) or
display any olfactory changes (Kurtenbach et al., 2013).
Anxiety-related behaviors were shown in one study (Zhu
et al., 2007) but were not confirmed by two other groups
(Perez and Palmiter, 2005; Rial et al., 2014). Similarly,
Park2− /− mice did not show a strong phenotype for
depression-like traits (Perez and Palmiter, 2005; Rial
et al., 2014). Interestingly, most studies have shown
effects on cognition and working memory. Park2− /−
mice have impaired habituation and exploratory activity
in a novel environment (Itier, 2003; Zhu et al., 2007) and
exhibit worse object location performance in a Y maze
(Rial et al., 2014). Additionally, they show less sponta-
neous alternation in a T-maze. There is no evidence of
impaired sensorimotor gating, although one study found a
reduced acoustic startle response (von Coelln et al., 2004)
concomitant with a selective reduction of Th-positive
neurons in the locus coeruleus and noradrenaline-
positive neurons in the spinal cord and olfactory bulb.
Unfortunately, biochemical and electrophysiological
evaluation of these models is not clear. Although no
studies have reported DA neuron degeneration, some
research has found an increase of DA leakage from nerve
terminals (Rial et al., 2014), higher extracellular levels of
DA in the striatum, and an increase in DAT expression
(Itier, 2003). Long-term potentiation was decreased in
one study, and a higher rate of paired pulse facilitation
and excitatory postsynaptic potentials was found after
low-frequency stimulation (Itier, 2003). Proteomic stu-
dies highlighted a strong reduction in mitochondrial
respiratory chain proteins and stress response proteins
(Shin et al., 2011) together with mitochondrial damage
(Stichel et al., 2007). Lack of Park2 also seems to affect
mitochondrial morphology (Pinto et al., 2018). The great
variability among Park2− /− mouse models could be
related to the background line and the type of mutation
introduced (Perez and Palmiter, 2005). The absence of a
strong Parkinsonian phenotype in Parkin-deficient mice
may be because of the presence of compensatory systems
such as multiple redundant E3 ubiquitin ligases.
Although Park2− /− mice have not been subjected to
tests for core features of ADHD, they do show impair-
ments in working memory, a feature shared by both
patients with ADHD and those with ASD (Craig et al.,
2016). Specifically, the impairments in spontaneous
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alternation and exploration of a novel environment (Itier,
2003) might mirror the restricted interest and cognitive
rigidity that are shown by some mouse models of ASD
(Kazdoba et al., 2016). A reduced acoustic startle response
has been also shown in other mouse ASD models
(DeLorey et al., 2011; Wurzman et al., 2015), and might
be linked to the inattention that characterizes patients
with ADHD. There are no published findings regarding
social behavior or impulsivity, making it difficult to fur-
ther speculate about the similarity of this model to
ADHD or ASD phenotypes.
Zebrafish
Park2 protein is extensively expressed in ventral dien-
cephalic DA neurons in zebrafish (Pienaar et al., 2010).
No stable park2 mutants are available in this species.
Transient KO zebrafish have been created and these
show no motor impairments. Interestingly, one of these
models showed a loss of neurons, and despite showing a
normal mitochondrial subset, complex I activity was
found to be reduced (Table 2; Flinn et al., 2009).
Similarly, KO of park2 increased cellular susceptibility to
stress, whereas overexpression of human PARK2 exerted
a general protective effect against the same conditions
(Fett et al., 2010).
Fruit fly
PARK2 protein is highly expressed in Drosophila and a
number of studies have begun to unravel the biological
functions of PARK2 in this organism. Generation of
PARK2/PINK1 double mutants has been crucial to
understand the PARK2 signalling pathway and identify
protein substrates (Botella et al., 2009; Pienaar et al., 2010;
Guo, 2012). Park− /− Drosophila have a short life span and
a low body weight (Table 3). The most prominent fea-
ture of these mutants is mitochondrial disintegration
(fragmented mitochondrial networks), advanced aging,
and loss of inner cristae (Cackovic et al., 2018). Moreover,
failure of mitochondrial dynamics leads to male sterility
and most probably to muscle degeneration, leaving the
flies unable to jump or fly. Variable results have been
reported regarding degeneration of a small subset of DA
neurons (Greene et al., 2003; Cha et al., 2005; Pesah et al.,
2005; Whitworth et al., 2005; Riparbelli and Callaini, 2007;
Vincent et al., 2012; Navarro et al., 2014). Overexpression
of mutant isoforms of PARK2 leads to a more pronounced
age-dependent loss of DA neurons (Sang et al., 2007).
A recent study reported learning and memory abnormal-
ities in park− /− and a weakening of circadian rhythms
because of changes in clock neurons (Julienne et al., 2017).
Human induced pluripotent stem cells
At the present time, 12 different hiPSC lines with various
CNVs and mutations in the PARK2 locus have been
created (Table 4) (Xu et al., 2016). All the donors were
diagnosed with Parkinson’s disease, and no hiPSC study
has been carried out using ASD or ADHD donors. The
creation of human midbrain DA neurons from these stem
cells uncovered an increase of DA release from terminals
accompanied by decreased DAT expression and lower
reuptake (Jiang et al., 2012). The same cells show a
diminished degree of neuronal process complexity,
measured by different features such as length, number of
terminals, and branch points, probably because of
microtubule instability (Ren et al., 2015). The rate of DA
differentiation is lower in hiPSCs carrying PARK2
mutations than in controls (Shaltouki et al., 2015). Most
studies have found impairment in mitochondrial mor-
phology (Imaizumi et al., 2012; Shaltouki et al., 2015;
Zanon et al., 2017) and complex I activity (Zanon et al.,
2017) together with an increase in the presence of reac-
tive oxygen species and a decrease in antioxidative
pathways (Chang et al., 2016; Suzuki et al., 2017). An
impairment in mitophagy has also been demonstrated
(Suzuki et al., 2017).
Discussion
The comparison of CNTNAP2, ADGRL3, and PARK2
across species has shown how these models can link
genetic variants found in human populations to ADHD
and ASD at both behavioral and neurobiological levels
(Table 5). Transgenic animal models of CNTNAP2, a
gene coding for a neuron–glia adhesion protein found in
myelinated axons, show that this gene is essential for
normal neurodevelopment. Depletion of CNTNAP2 in
mice results in epileptic seizures and a reduction in the
number of GABAergic interneurons (Crawley et al., 1997;
Penagarikano et al., 2011). The same features are found
in the equivalent zebrafish model, which shows a smaller
head and increased sensitivity to drug-induced seizures
(Hoffman et al., 2016). The phenotype is even stronger in
Drosophila where the absence of the CNTNAP2 ortho-
logues results in late-stage embryonic lethality (Zweier
et al., 2009). Finally, neural progenitor cells derived from
a heterozygous CNTNAP2 patient show significantly
reduced neural migration (Lee et al., 2015), and hiPSC-
derived neurons from carrier individuals show differential
expression of genes involved in synaptic transmission and
neuronal activity (Flaherty et al., 2017). Interneuron
dysfunction has been repeatedly linked with ASD
(Takano, 2015). On a behavioral level, some phenotypic
features are common across species such as the hyper-
activity seen in both mice and zebrafish (Penagarikano
et al., 2011; Hoffman et al., 2016). This hyperactivity
mirrors one of the most prominent symptoms of ADHD.
The biological role of ADGRL3 is also linked to trans-
cellular adhesion and glutamatergic synapse develop-
ment (Jackson et al., 2015). Multiple models of ADGRL3
have displayed alterations in their DA system including
increased dopamine levels in ADGRL3 mutant mice and
a reduced number of DA neurons in adgrl3.1 morphant
zebrafish (Lange et al., 2012; Orsini et al., 2016). Dysregulation
of dopamine has been implicated in the etiology of ADHD
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by both genetic and functional imaging studies (Li et al., 2006;
Faraone et al., 2015), and the most effective pharmacological
treatments for ADHD are stimulant medications that act on
the DA and noradrenergic systems (Engert and Pruessner,
2008). Behavioral analysis of ADGRL3 transgenic animals has
revealed a number of phenotypes, the most prominent of
which is the cross-species hyperactivity, which is modulated
by light in Drosophila. The impairment of DA signalling in
ADGRL3 transgenic animals could provide insights into how
genes not directly involved in this neurotransmitter pathway
may confer increased risk of ADHD.
Although mutations in the PARK2 gene are historically
linked with Parkinson’s disease, mouse and zebrafish do
not robustly model this disease (Perez and Palmiter,
2005). Instead, knockout of Park2 in both mouse and
Drosophila leads to ADHD-like impairments in working
memory. Most PARK2 models show mitochondrial phe-
notypes including fragmented mitochondrial networks in
Drosophila and disrupted mitophagy, mitochondrial mor-
phology, and complex I activity in neurons derived from
iPSCs of patients with various genetic abnormalities in
PARK2 (Imaizumi et al., 2012; Shaltouki et al., 2015;
Zanon et al., 2017). Different studies have underlined an
association between ASD, ADHD, and mitochondrial
impairment. General mitochondrial dysfunction is
believed to be present in 30–40% of autistic children
(Giulivi et al., 2010; Rossignol and Frye, 2011; Morris and
Berk, 2015). With regards to ADHD, sporadic mtDNA
mutations and increases in oxidative markers have been
reported (Marazziti et al., 2011), as well as lower levels of
oxygen consumption and ATP production together with
increased levels of superoxide radicals (Verma et al.,
2016).
PARK2 hiPSC models also indicate an impairment in the
DA system. Midbrain DA neurons created from these
hiPSC lines showed an increase in DA release from
terminals accompanied by lower reuptake of this neuro-
transmitter (Jiang et al., 2012). The same cells show a
diminished degree of neuronal process complexity,
probably because of microtubule instability (Ren et al.,
2015).
Conclusion
In this review, we highlight the use of animal and cellular
models to study neuropsychiatric disorders. By focusing
on three genes that are linked to one or more psychiatric
disorders, we have shown that comparing phenotypes
across different species can provide more convincing
insights into the aetiology of these diseases. Examples of
this include the link between ADGRL3.1 and DA sig-
nalling, and PARK2 and mitochondrial dysfunction.
Despite the difficulties in recapitulating complex human
diseases, animal models are vital to identify novel treat-
ments. Moreover, the advent of hiPSC models may
generate novel insights into pathophysiology as they can
mirror the heterogeneous genetic background typical of
ADHD and ASD in a manner that is difficult to achieve
in animal models. The diversity of genetic variants
associated with neurodevelopmental disorders including
ASD may be explained by their downstream con-
vergence on biological processes such as synapse devel-
opment and neurotransmission (Sanders, 2015). In the
future, additional hiPSC models and more complex ani-
mal models of ASD and ADHD coupled with stringent
testing will be necessary to unravel the molecular
mechanisms underlying these disorders and to develop
novel treatments for them.
Acknowledgements
The project is funded by the European Union’s Horizon
2020 research and innovation program under grant
agreement no 643051.
E.D.V., N.M., and V.S.P. are early-stage researchers in
the MiND Marie Sklodowska-Curie who received
funding from the European Union’s Horizon 2020
research and innovation program under grant agreement
no 643051. S.K.S., K.P.L., A.R., A.S., and W.H.J.N. are
PIs, and W.H.J.N. is leader of the animal work package in
the MiND project. The authors thank Dr Olga Rivero,
Dr Marta Ribases, and Prof. Barbara Franke for their
supervision and support during the preparation of this
review.
Conflicts of interest
There are no conflicts of interest.
References
Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA,
et al. (2013). SFARI Gene 2.0: a community-driven knowledgebase for the
autism spectrum disorders (ASDs). Mol Autism 4:36.
Amores A, Catchen J, Ferrara A, Fontenot Q, Postlethwait JH (2011). Genome
evolution and meiotic maps by massively parallel DNA sequencing: spotted
gar, an outgroup for the teleost genome duplication. Genetics 188:799–808.
Arcos-Burgos, M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, et al.
(2010). A common variant of the latrophilin 3 gene, LPHN3, confers sus-
ceptibility to ADHD and predicts effectiveness of stimulant medication. Mol
Psychiatry 15:1053–1066.
Table 5 Overview of genes linked to attention-deficit/hyperactivity disorder and autism spectrum disorder
Genes Linked disorder Gene function Main phenotype
CNTNAP2 ASD Neuron–glia adhesion (voltage-gated K channel localization) Interneurons disfunction
ADGRL3 ADHD Transcellular adhesion/glutammatergic synapse development Dopaminergic alteration
PARK2 ASD
ADHD
E3 Ub protein ligase (mitochondria quality control) Mitochondrial impairment
Dopaminergic disfunction
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
Cross-species models of ADHD/ASD Dalla Vecchia et al. 13
Arcos-Burgos M, Vélez JI, Solomon BD, Muenke M (2012). A common genetic
network underlies substance use disorders and disruptive or externalizing
disorders. Hum Genet 131:917–929.
Ardhanareeswaran K, Coppola G, Vaccarino F (2015). The use of stem cells to
study autism spectrum disorder. Yale J Biol Med 88:5–16.
Ardhanareeswaran K, Mariani J, Coppola G, Abyzov A, Vaccarino FM (2017).
Human induced pluripotent stem cells for modelling neurodevelopmental
disorders. Nat Rev Neurol 13:265–278.
Arguello PA, Gogos JA (2006). Modeling madness in mice: one piece at a time.
Neuron 52:179–196.
Arora M, Reichenberg A, Willfors C, Austin C, Gennings C, Berggren S, et al.
(2017). Fetal and postnatal metal dysregulation in autism. Nat Commun
8:15493.
Baig DN, Yanagawa T, Tabuchi K (2017). Distortion of the normal function of
synaptic cell adhesion molecules by genetic variants as a risk for autism
spectrum disorders. Brain Res Bull 129:82–90.
Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T
(2006). Prevalence of disorders of the autism spectrum in a population cohort
of children in South Thames: the Special Needs and Autism Project (SNAP).
Lancet 368:210–215.
Bellen HJ, Tong C, Tsuda H (2010). 100 years of Drosophila research and its
impact on vertebrate neuroscience: a history lesson for the future. Nat Rev
Neurosci 11:514–522.
Bier E (2005). Drosophila, the golden bug, emerges as a tool for human genetics.
Nat Rev Genet 6:9–23.
Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S,
et al. (2012). The global economic burden of noncommunicable diseases.
PGDA Working Papers 8712, Program on the Global Demography of Aging.
Blum M, De Robertis EM, Wallingford JB, Niehrs C (2015). Morpholinos: anti-
sense and sensibility. Dev Cell 35:145–149.
Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S (2009). Modelling
Parkinson’s disease in Drosophila. Neuromolecular Med 11:268–280.
Boukhris T, Sheehy O, Mottron L, Bérard A (2016). Antidepressant use during
pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr
170:117–124.
Brand AH, Perrimon N (1993). Targeted gene expression as a means of altering
cell fates and generating dominant phenotypes. Development 118:401–415.
Brikell I, Kuja-Halkola R, Larsson H (2015). Heritability of attention-deficit hyper-
activity disorder in adults. Am J Med Genet B Neuropsychiatr Genet
168:406–413.
Cackovic J, Gutierrez-Luke S, Call GB, Juba A, O'Brien S, Jun CH, et al. (2018).
Vulnerable parkin loss-of-function Drosophila dopaminergic neurons have
advanced mitochondrial aging, mitochondrial network loss and transiently
reduced autophagosome recruitment. Front Cell Neurosci 12:39.
Caglayan AO (2010). Genetic causes of syndromic and non-syndromic autism.
Dev Med Child Neurol 52:130–138.
Cha GH, Kim S, Park J, Lee E, Kim M, Lee SB, et al. (2005). Parkin negatively
regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl
Acad Sci USA 102:10345–10350.
Chang K-H, Lee-Chen GJ, Wu YR, Chen YJ, Lin JL, Li M, et al. (2016). Impairment
of proteasome and anti-oxidative pathways in the induced pluripotent stem
cell model for sporadic Parkinson’s disease. Parkinsonism Relat Disord
24:81–88.
Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC,
et al. (2005). Mice lacking Dlx1 show subtype-specific loss of interneurons,
reduced inhibition and epilepsy. Nat Neurosci 8:1059–1068.
Autism Spectrum Disorders Working Group of The Psychiatric Genomics
Consortium (2017). Meta-analysis of GWAS of over 16 000 individuals with
autism spectrum disorder highlights a novel locus at 10q24. 32 and a sig-
nificant overlap with schizophrenia. Mol Autism 8:1–17.
Craig F, Margari F, Legrottaglie AR, Palumbi R, de Giambattista C, Margari L
(2016). A review of executive function deficits in autism spectrum disorder
and attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat
12:1191–1202.
Crawley JN (2012). Translational animal models of autism and neurodevelop-
mental disorders. Dialogues Clin Neurosci 14:293–305.
Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al.
(1997). Behavioral phenotypes of inbred mouse strains: implications and
recommendations for molecular studies. Psychopharmacology (Berl)
132:107–124.
da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A, et al. (2009).
Transcriptional repression of p53 by parkin and impairment by mutations
associated with autosomal recessive juvenile Parkinson's disease. Nat Cell
Biol 11:1370–1375.
Davletov BA, Shamotienko OG, Lelianova VG, Grishin EV, Ushkaryov YA (1996).
Isolation and biochemical characterization of a Ca2+ -independent alpha-
latrotoxin-binding protein. J Biol Chem 271:23239–23245.
DeLorey TM, Sahbaie P, Hashemi E, Li WW, Salehi A, Clark DJ (2011).
Somatosensory and sensorimotor consequences associated with the het-
erozygous disruption of the autism candidate gene, Gabrb3. Behav Brain Res
216:36–45.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (2017).
Discovery of the first genome-wide significant risk loci for ADHD. bioRxiv. doi:
dx.doi.org/10.1101/145581.
American Psychiatric Association (2013). Diagnostic and statistical manual of
mental disorders. USA: American Psychiatric Association.
Elia J, Gai X, Xie HM, Perin JC, Geiger E, Glessner JT, et al. (2010). Rare
structural variants found in attention-deficit hyperactivity disorder are pre-
ferentially associated with neurodevelopmental genes. Mol Psychiatry
15:637–646.
Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, Hadley D, et al. (2012).
Genome-wide copy number variation study associates metabotropic gluta-
mate receptor gene networks with attention deficit hyperactivity disorder. Nat
Genet 44:78.
Engert V, Pruessner JC (2008). Dopaminergic and noradrenergic contributions to
functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol
6:322–328.
Falk A, Heine VM, Harwood AJ, Sullivan PF, Peitz M, Brüstle O, et al. (2016).
Modeling psychiatric disorders: from genomic findings to cellular phenotypes.
Mol Psychiatry 21:1167–1179.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-
Quiroga JA, et al. (2015). Attention-deficit/hyperactivity disorder. Nat Rev Dis
Primers 1:15020.
Fernandez BA, Scherer SW (2017). Syndromic autism spectrum disorders:
moving from a clinically defined to a molecularly defined approach. Dialogues
Clin Neurosci 19:353–371.
Fett ME, Pilsl A, Paquet D, van Bebber F, Haass C, Tatzelt J, et al. (2010). Parkin is
protective against proteotoxic stress in a transgenic zebrafish model. PLoS
ONE 5:11783.
Flaherty E, Deranieh RM, Artimovich E, Lee IS, Siegel AJ, Levy DL, et al. (2017).
Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions dis-
play altered neuronal gene expression and network activity. NPJ Schizophr
3:35.
Flinn L, Mortiboys H, Volkmann K, Köster RW, Ingham PW, Bandmann O (2009).
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient
zebrafish (Danio rerio). Brain 132:1613–1623.
Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA, et al.
(2012). The genetics of attention deficit/hyperactivity disorder in adults,
a review. Mol Psychiatry 17:960–987.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al.
(2018). Live fast, die young? A review on the developmental trajectories of
ADHD across the lifespan. Eur Neuropsychopharmacol 28:1059–1088.
Frega M, van Gestel SH, Linda K, van der Raadt J, Keller J, Van Rhijn JR, et al.
(2017). Rapid neuronal differentiation of induced pluripotent stem cells for
measuring network activity on micro-electrode arrays. J Vis Exp. doi: 10.3791/
54900.
Gau JM, Stice E, Rohde P, Seeley JR (2012). Negative life events and substance
use moderate cognitive behavioral adolescent depression prevention inter-
vention. Cogn Behav Ther 41:241–250.
Ghirardi L, Brikell I, Kuja-Halkola R, Freitag CM, Franke B, Asherson P, et al.
(2018). The familial co-aggregation of ASD and ADHD: a register-based
cohort study. Mol Psychiatry 23:257–262.
Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Hertz-Picciotto I,
et al. (2010). Mitochondrial dysfunction in autism. JAMA 304:2389–2396.
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. (2009). Autism
genome-wide copy number variation reveals ubiquitin and neuronal genes.
Nature 459:569–573.
Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al.
(2003). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of
dopaminergic neurons. J Biol Chem 278:43628–43635.
Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003).
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila
parkin mutants. Proc Natl Acad Sci USA 100:4078–4083.
Guo M (2012). Drosophila as a model to study mitochondrial dysfunction in
Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009944–a009944.
Gutiérrez HC, Vacca I, Pons AI, Norton W (2018). Automatic quantification of
juvenile zebrafish aggression. J Neurosci Methods 296:23–31.
Halmøy A, Klungsøyr K, Skjærven R, Haavik J (2012). Pre- and perinatal risk
factors in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry
71:474–481.
14 Psychiatric Genetics 2019, Vol 29 No 1
Hang L, Thundyil J, Lim KL (2015). Mitochondrial dysfunction and Parkinson
disease: a Parkin-AMPK alliance in neuroprotection. Ann N Y Acad Sci
1350:37–47.
Hara S, Takada S (2017). Genome editing for the reproduction and remedy of
human diseases in mice. J Hum Genet 63:107–113.
Hartman CA, Geurts HM, Franke B, Buitelaar JK, Rommelse N (2016). Changing
ASD-ADHD symptom co-occurrence across the lifespan with adolescence as
crucial time window: illustrating the need to go beyond childhood. Neurosci
Biobehav Rev 71:529–541.
Hawi Z, Cummins TD, Tong J, Johnson B, Lau R, Samarrai W, et al. (2015). The
molecular genetic architecture of attention deficit hyperactivity disorder. Mol
Psychiatry 20:289–297.
Hoffman EJ, Turner KJ, Fernandez JM, Cifuentes D, Ghosh M, Ijaz S, et al. (2016).
Estrogens suppress a behavioral phenotype in zebrafish mutants of the autism
risk gene, CNTNAP2. Neuron 89:725–733.
Hoffman GE, Schrode N, Flaherty E, Brennand KJ (2018). New considerations for
hiPSC-based models of neuropsychiatric disorders. Mol Psychiatry. doi:
10.1038/s41380-018-0029-1.
Hollville E, Carroll RG, Cullen SP, Martin SJ (2014). Bcl-2 Family proteins parti-
cipate in mitochondrial quality control by regulating Parkin/PINK1-dependent
mitophagy. Mol Cell 55:451–466.
Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. (2013).
The zebrafish reference genome sequence and its relationship to the
human genome. Nature 496:498–503.
Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, et al.
(2012). Mitochondrial dysfunction associated with increased oxidative stress
and α-synuclein accumulation in PARK2 iPSC-derived neurons and post-
mortem brain tissue. Mol Brain 5:35.
Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, et al.
(2003). Parkin gene inactivation alters behaviour and dopamine neuro-
transmission in the mouse. Hum Mol Genet 12:2277–2291.
Jackson VA, del Toro D, Carrasquero M, Roversi P, Harlos K, Klein R, et al. (2015).
Structural basis of latrophilin–FLRT interaction. Structure 23:774–781.
Jansch C, Günther K, Waider J, Ziegler GC, Forero A, Kollert S, et al. (2018).
Generation of a human induced pluripotent stem cell (iPSC) line from a
51-year-old female with attention-deficit/hyperactivity disorder (ADHD) car-
rying a duplication of SLC2A3. Stem Cell Res 28:136–140.
Jarick I, Volckmar AL, Pütter C, Pechlivanis S, Nguyen TT, Dauvermann MR, et al.
(2014). Genome-wide analysis of rare copy number variations reveals PARK2
as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry
19:115–121.
Jarick I, Volckmar AL, Pütter C, Pechlivanis S, Nguyen TT, Dauvermann MR, et al.
(2014). Genome-wide analysis of rare copy number variations reveals PARK2
as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry
19:115–121.
Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, et al. (2012). Parkin controls
dopamine utilization in human midbrain dopaminergic neurons derived from
induced pluripotent stem cells. Nat Commun 3:668.
Julienne H, Buhl E, Leslie DS, Hodge J (2017). Drosophila PINK1 and parkin loss-
of-function mutants display a range of non-motor Parkinson’s disease phe-
notypes. Neurobiol Dis 104:15–23.
Jurgensen S, Castillo E, Leslie PE (2015). Selective Dysregulation of
Hippocampal Inhibition in the Mouse Lacking Autism Candidate Gene
CNTNAP2. J Neurosci 35:14681–14687.
Kazdoba T, Leach P, Crawley JN (2016). Behavioral phenotypes of genetic mouse
models of autism. Genes Brain Behav 15:7–26.
Kim Y, Rim YA, Yi H, Park N, Park SH, Ju JH (2016). The generation of human
induced pluripotent stem cells from blood cells: an efficient protocol using
serial plating of reprogrammed cells by centrifugation. Stem Cells Int
2016:1329459.
Kiser DP, Rivero O, Lesch KP (2015). Annual research review: the (epi)genetics
of neurodevelopmental disorders in the era of whole-genome sequencing –
unveiling the dark matter. J Child Psychol Psychiatry 56:278–295.
Kurtenbach S, Wewering S, Hatt H, Neuhaus EM, Lübbert H (2013). Olfaction in
three genetic and two MPTP-induced Parkinson’s disease mouse models.
PLoS One 8:77509.
Lange M, Norton W, Coolen M, Chaminade M, Merker S, Proft F, et al. (2012).
The ADHD-susceptibility gene lphn3. 1 modulates dopaminergic neuron for-
mation and locomotor activity during zebrafish development. Mol Psychiatry
17:946–954.
Lange M, Froc C, Grunwald H, Norton W, Bally-Cuif L (2018). Pharmacological
analysis of zebrafish lphn3. 1 morphant larvae suggests that saturated
dopaminergic signaling could underlie the ADHD-like locomotor hyperactivity.
Prog Neuropsychopharmacol Biol Psychiatry 84:181–189.
LeClerc S, Easley D (2015). Pharmacological therapies for autism spectrum
disorder: a review. P T 40:389–397.
Lee IS, Carvalho CM, Douvaras P, Ho SM, Hartley BJ, Zuccherato LW, et al.
(2015). Characterization of molecular and cellular phenotypes associated
with a heterozygous CNTNAP2 deletion using patient-derived hiPSC
neural cells. NPJ Schizophr 1:15019.
Lesch K-P, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T, et al. (2011).
Genome-wide copy number variation analysis in attention-deficit/hyperactivity
disorder: association with neuropeptide Y gene dosage in an extended ped-
igree. Mol Psychiatry 16:491–503.
Li D, Sham PC, Owen MJ, He L (2006). Meta-analysis shows significant asso-
ciation between dopamine system genes and attention deficit hyperactivity
disorder (ADHD). Hum Mol Genet 15:2276–2284.
Li J, Ashley J, Budnik V, Bhat MA (2007). Crucial role of Drosophila neurexin in
proper active zone apposition to postsynaptic densities, synaptic growth, and
synaptic transmission. Neuron 55:741–755.
Li Z, Chang SH, Zhang LY, Gao L, Wang J (2014). Molecular genetic studies of
ADHD and its candidate genes: a review. Psychiatry Res 219:10–24.
Lim C-S, Yang JE, Lee YK, Lee K, Lee JA, Kaang BK (2015). Understanding the
molecular basis of autism in a dish using hiPSCs-derived neurons from ASD
patients. Mol Brain 8:57.
Lionel AC, Crosbie J, Barbosa N, Goodale T, Thiruvahindrapuram B, Rickaby J,
et al. (2011). Rare copy number variation discovery and cross-disorder
comparisons identify risk genes for ADHD. Sci Transl Med 3:95ra75.
Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. (2000).
Association between early-onset Parkinson’s disease and mutations in the
parkin gene. N Engl J Med 342:1560–1567.
Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni E, et al. (2011).
Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem 18:
4715–4721.
Martinez AF, Abe Y, Hong S, Molyneux K, Yarnell D, Löhr H, et al. (2016). An
Ultraconserved brain-specific enhancer within ADGRL3 (LPHN3) underpins
attention-deficit/hyperactivity disorder susceptibility. Biol Psychiatry
80:943–954.
McCammon JM, Sive H (2015). Addressing the genetics of human mental health
disorders in model organisms. Annu Rev Genomics Hum Genet 16:173–197.
Meadows SO, McLanahan S, Brooks-Gunn J (2007). Parental depression and
anxiety and early childhood behavior problems across family types. J Marriage
Fam 69:1162–1177.
Modabbernia A, Velthorst E, Reichenberg A (2017). Environmental risk factors for
autism: an evidence-based review of systematic reviews and meta-analyses.
Mol Autism 8:13.
Morris G, Berk M (2015). The many roads to mitochondrial dysfunction in neu-
roimmune and neuropsychiatric disorders. BMC Med 13:68.
Müller-Rischart AK, Pilsl A, Beaudette P, Patra M, Hadian K, Funke M, et al.
(2013). The E3 ligase parkin maintains mitochondrial integrity by increasing
linear ubiquitination of NEMO. Mol Cell 49:908–921.
Navarro JA, Heßner S, Yenisetti SC, Bayersdorfer F, Zhang L, Voigt A, et al.
(2014). Analysis of dopaminergic neuronal dysfunction in genetic and toxin-
induced models of Parkinson’s disease in Drosophila. J Neurochem
131:369–382.
Nikolas MA, Burt SA (2010). Genetic and environmental influences on ADHD
symptom dimensions of inattention and hyperactivity: a meta-analysis.
J Abnorm Psychol 119:1–17.
Norton WHJ (2013). Toward developmental models of psychiatric disorders in
zebrafish. Front Neural Circuits 7:79.
Nussbaum NL (2012). ADHD and female specific concerns: a review of the
literature and clinical implications. J Atten Disord 16:87–100.
Orsini CA, Setlow B, DeJesus M, Galaviz S, Loesch K, Ioerger T, Wallis D (2016).
Behavioral and transcriptomic profiling of mice null forLphn3, a gene impli-
cated in ADHD and addiction. Mol Genet Genomic Med 4:322–343.
O’Kane CJ (2011). Drosophila as a model organism for the study of neuropsychiatric
disorders. Curr Top Behav Neurosci 7:37–60.
O’sullivan ML, Martini F, von Daake S, Comoletti D, Ghosh A (2014). LPHN3, a
presynaptic adhesion-GPCR implicated in ADHD, regulates the strength of
neocortical layer 2/3 synaptic input to layer 5. Neural Develop 9:7.
Peñagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H,
et al. (2011). Absence of CNTNAP2 leads to epilepsy, neuronal migration
abnormalities, and core autism-related deficits. Cell 147:235–246.
Perez FA, Palmiter RD (2005). Parkin-deficient mice are not a robust model of
parkinsonism. Proc Natl Acad Sci USA 102:2174–2179.
Pesah Y, Burgess H, Middlebrooks B, Ronningen K, Prosser J, Tirunagaru V, et al.
(2005). Whole-mount analysis reveals normal numbers of dopaminergic
neurons following misexpression of alpha-synuclein in Drosophila. Genesis
41:154–159.
Peñagarikano O, Geschwind DH (2012). What does CNTNAP2 reveal about
autism spectrum disorder? Trends Mol Med 18:156–163.
Cross-species models of ADHD/ASD Dalla Vecchia et al. 15
Pickrell MA, Youle JR (2015). The roles of PINK1, Parkin, and mitochondrial fidelity
in Parkinson’s disease. Neuron 85:257–273.
Pienaar IS, Götz J, Feany MB (2010). Parkinson’s disease: insights from non-
traditional model organisms. Prog Neurobiol 92:558–571.
Pinto M, Nissanka N, Moraes CT (2018). Lack of parkin anticipates the phenotype
and affects mitochondrial morphology and mtDNA levels in a mouse model of
Parkinson’s disease. J Neurosci 38:1042–1053.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007). The
worldwide prevalence of ADHD: a systematic review and metaregression
analysis. Am J Psychiatry 164:942–948.
Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer JL, et al. (1999).
Caspr2, a new member of the neurexin superfamily, is localized at the juxta-
paranodes of myelinated axons and associates with K+ channels. Neuron
24:1037–1047.
Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B, Pevny L, et al. (2003).
Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons
depends on Caspr2 and TAG-1. J Cell Biol 162:1149–1160.
Poot M (2015). Connecting the CNTNAP2 networks with neurodevelopmental
disorders. Mol Syndromol 6:7–22.
Poot M, Beyer V, Schwaab I, Damatova N, Van't Slot R, Prothero J, et al. (2010).
Disruption of CNTNAP2 and additional structural genome changes in a boy
with speech delay and autism spectrum disorder. Neurogenetics 11:81–89.
Port F, Chen HM, Lee T, Bullock SL (2014). Optimized CRISPR/Cas tools for
efficient germline and somatic genome engineering in Drosophila. Proc Natl
Acad Sci USA 111:2967–2976.
Prilutsky D, Palmer NP, Smedemark-Margulies N, Schlaeger TM, Margulies DM,
Kohane IS (2014). iPSC-derived neurons as a higher-throughput readout for
autism: promises and pitfalls. Trends Mol Med 20:91–104.
Prytkova I, Brennand KJ (2017). Prospects for modeling abnormal neuronal
function in schizophrenia using human induced pluripotent stem cells. Front
Cell Neurosci 11:360.
Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M (2009). OROS
methylphenidate for the treatment of adults with attention-deficit/hyperactivity
disorder. Expert Rev Neurother 9:1121–1131.
Ramos-Quiroga J-A, Sánchez-Mora C, Casas M, Garcia-Martínez I, Bosch R,
Nogueira M, et al. (2014). Genome-wide copy number variation analysis in
adult attention-deficit and hyperactivity disorder. J Psychiatr Res 49:60–67.
Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. (2006).
Global variation in copy number in the human genome. Nature 444:444–454.
Ren Y, Jiang H, Hu Z, Fan K, Wang J, Janoschka S, et al. (2015). Parkin mutations
reduce the complexity of neuronal processes in iPSC-derived human neurons.
Stem Cells 33:68–78.
Rial D, Castro AA, Machado N, Garção P, Gonçalves FQ, Silva HB, et al. (2014).
Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical
features of Parkinson’s disease. PLoS One 9:114216.
Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, Bosch R, Richarte V,
Palomar G, et al. (2011). Contribution of LPHN3 to the genetic susceptibility
to ADHD in adulthood: a replication study. Genes Brain Behav 10:149–157.
Rihel J, Prober DA, Schier AF (2010). Monitoring sleep and arousal in zebrafish.
Methods Cell Biol 281–294.
Riparbelli MG, Callaini G (2007). The Drosophila parkin homologue is required for
normal mitochondrial dynamics during spermiogenesis. Dev Biol 303:108–120.
Rivero O, Selten MM, Sich S, Popp S, Bacmeister L, Amendola E, et al. (2015).
Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic
function in hippocampus and cognition. Transl Psychiatry 5:655–e655.
Rodenas-Cuadrado P, Ho J, Vernes SC (2014). Shining a light on CNTNAP2:
complex functions to complex disorders. Eur J Hum Genet 22:171–178.
Rommelse NN, Geurts HM, Franke B, Buitelaar JK, Hartman CA (2011). A review
on cognitive and brain endophenotypes that may be common in autism
spectrum disorder and attention-deficit/hyperactivity disorder and facilitate
the search for pleiotropic genes. Neurosci Biobehav Rev 35:1363–1396.
Rosen BN, Lee BK, Lee NL, Yang Y, Burstyn I (2014). Maternal smoking and autism
spectrum disorder: a meta-analysis. J Autism Dev Disord 45:1689–1698.
Rossignol DA, Frye RE (2012). Mitochondrial dysfunction in autism spectrum dis-
orders: a systematic review and meta-analysis. Mol Psychiatry 17:290–314.
Rubenstein JL, Merzenich MM (2003). Model of autism: increased ratio of exci-
tation/inhibition in key neural systems. Genes Brain Behav 2:255–267.
Rubin GM, Spradling AC (1982). Genetic transformation of Drosophila with
transposable element vectors. Science 218:348–353.
Sanders SJ (2015). First glimpses of the neurobiology of autism spectrum dis-
order. Curr Opin Genet Dev 33:80–92.
Sang TK, Chang HY, Lawless GM, Ratnaparkhi A, Mee L, Ackerson LC, et al.
(2007). A Drosophila model of mutant human parkin-induced toxicity
demonstrates selective loss of dopaminergic neurons and dependence on
cellular dopamine. J Neurosci 27:981–992.
Scarffe LA, Stevens DA, Dawson VL, Dawson TM (2014). Parkin and PINK1:
much more than mitophagy. Trends Neurosci 37:315–324.
Scheuerle A, Wilson K (2011). PARK2 copy number aberrations in two children
presenting with autism spectrum disorder: further support of an association
and possible evidence for a new microdeletion/microduplication syndrome.
Am J Med Genet B Neuropsychiatr Genet 156:413–420.
Schmid B, Haass C (2013). Genomic editing opens new avenues for zebrafish as
a model for neurodegeneration. J Neurochem 127:461–470.
Sciberras E, Mulraney M, Silva D, Coghill D (2017). Prenatal risk factors and the
etiology of ADHD: review of existing evidence. Curr Psychiatry Rep 19:1.
Shaltouki A, Sivapatham R, Pei Y, Gerencser AA, Momčilović O, Rao MS, et al.
(2015). Mitochondrial alterations by PARKIN in dopaminergic neurons using
PARK2 Patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell
Reports 4:847–859.
Shang Y, Haynes P, Pírez N, Harrington KI, Guo F, Pollack J, et al. (2011). Imaging
analysis of clock neurons reveals light buffers the wake-promoting effect of
dopamine. Nat Neurosci 14:889–895.
Shin J-H, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, et al. (2011). PARIS
(ZNF746) repression of PGC-1α contributes to neurodegeneration in
Parkinson’s disease. Cell 144:689–702.
Shishido E, Aleksic B, Ozaki N (2014). Copy-number variation in the pathogenesis
of autism spectrum disorder. Psychiatry Clin Neurosci 68:85–95.
Sjaarda CP, Hecht P, McNaughton A, Zhou A, Hudson ML, Will MJ, et al. (2017).
Interplay between maternal Slc6a4 mutation and prenatal stress: a possible
mechanism for autistic behavior development. Sci Rep 7:8735.
Soliman MA, Aboharb F, Zeltner N, Studer L (2017). Pluripotent stem cells in
neuropsychiatric disorders. Mol Psychiatry 22:1241–1249.
Stewart AM, Nguyen M, Wong K, Poudel MK, Kalueff AV (2014). Developing zeb-
rafish models of autism spectrum disorder (ASD). Prog Neuropsychopharmacol
Biol Psychiatry 50:27–36.
Stewart AM, Ullmann JF, Norton WH, Parker MO, Brennan CH, Gerlai R, et al.
(2015). Molecular psychiatry of zebrafish. Mol Psychiatry 20:2–17.
Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lübbert H (2007). Mono-
and double-mutant mouse models of Parkinson’s disease display severe
mitochondrial damage. Hum Mol Genet 16:2377–2393.
Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM,
et al. (2006). Recessive symptomatic focal epilepsy and mutant contactin-
associated protein-like 2. N Engl J Med 354:1370–1377.
Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, et al.
(2017). Associations of maternal antidepressant use during the first trimester
of pregnancy with preterm birth, small for gestational age, autism spectrum
disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA
317:1553–1562.
Suzuki S, Akamatsu W, Kisa F, Sone T, Ishikawa KI, Kuzumaki N, et al. (2017).
Efficient induction of dopaminergic neuron differentiation from induced plur-
ipotent stem cells reveals impaired mitophagy in PARK2 neurons. Biochem
Biophys Res Commun 483:88–93.
Sánchez-Mora C, Richarte V, Garcia-Martínez I, Pagerols M, Corrales M, Bosch R,
et al. (2015). Dopamine receptor DRD4 gene and stressful life events in
persistent attention deficit hyperactivity disorder. Am J Med Genet B
Neuropsychiatr Genet 168:480–491.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. (2007).
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131:861–872.
Takano T (2015). Interneuron dysfunction in syndromic autism: recent advances.
Dev Neurosci 37:467–475.
Tay TL, Ronneberger O, Ryu S, Nitschke R, Driever W (2011). Comprehensive
catecholaminergic projectome analysis reveals single-neuron integration of zeb-
rafish ascending and descending dopaminergic systems. Nat Commun 2:171.
Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F (2016). Heritability of autism
spectrum disorders: a meta-analysis of twin studies. J Child Psychol
Psychiatry 57:585–595.
van Alphen B, van Swinderen B (2013). Drosophila strategies to study psychiatric
disorders. Brain Res Bull 92:1–11.
van der Voet M, Nijhof B, Oortveld MA, Schenck A (2014). Drosophila models of
early onset cognitive disorders and their clinical applications. Neurosci
Biobehav Rev 46 Pt 2:326–342.
van der Voet M, Harich B, Franke B, Schenck A (2016). ADHD-associated
dopamine transporter, latrophilin and neurofibromin share a dopamine-related
locomotor signature in Drosophila. Mol Psychiatry 21:565–573.
Vandamme TF (2014). Use of rodents as models of human diseases. J Pharm
Bioallied Sci 6:2–9.
Verma P, Singh A, Nthenge-Ngumbau DN, Rajamma U, Sinha S,
Mukhopadhyay K, et al. (2016). Attention deficit-hyperactivity disorder suffers
from mitochondrial dysfunction. BBA Clin 6:153–158.
16 Psychiatric Genetics 2019, Vol 29 No 1
Vigo D, Thornicroft G, Atun R (2016). Estimating the true global burden of mental
illness. Lancet Psychiatry 3:171–178.
Vincent A, Briggs L, Chatwin GF, Emery E, Tomlins R, Oswald M, et al. (2012). Parkin-
induced defects in neurophysiology and locomotion are generated by metabolic
dysfunction and not oxidative stress. Hum Mol Genet 21:1760–1769.
von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. (2004). Loss
of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl
Acad Sci USA 101:10744–10749.
Wagh DA, Rasse TM, Asan E, Hofbauer A, Schwenkert I, Dürrbeck H, et al.
(2006). Bruchpilot, a protein with homology to ELKS/CAST, is required for
structural integrity and function of synaptic active zones in Drosophila. Neuron
49:833–844.
Wallis D, Hill DS, Mendez IA, Abbott LC, Finnell RH, Wellman PJ, et al. (2012).
Initial characterization of mice null for Lphn3, a gene implicated in ADHD and
addiction. Brain Res 1463:85–92.
Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ (2005).
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in
aDrosophilamodel of Parkinson’s disease. Proc Natl Acad Sci 102:8024–8029.
Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R, et al.
(2010). Rare chromosomal deletions and duplications in attention-deficit
hyperactivity disorder: a genome-wide analysis. Lancet 376:1401–1408.
Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, Gill M, et al. (2012).
Genome-wide analysis of copy number variants in attention deficit hyper-
activity disorder: the role of rare variants and duplications at 15q13. 3. Am J
Psychiatry 169:195–204.
Wolraich ML, Doffing MA (2004). Pharmacokinetic considerations in the treat-
ment of attention-deficit hyperactivity disorder with methylphenidate. CNS
Drugs 18:243–250.
Wong AH, Josselyn SA (2016). Caution when diagnosing your mouse with
schizophrenia: the use and misuse of model animals for understanding
psychiatric disorders. Biol Psychiatry 79:32–38.
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z (2017). Advanced parental age and
autism risk in children: a systematic review and meta-analysis. Acta Psychiatr
Scand 135:29–41.
Wurzman R, Forcelli PA, Griffey CJ, Kromer LF (2015). Repetitive grooming and
sensorimotor abnormalities in an ephrin-A knockout model for autism spec-
trum disorders. Behav Brain Res 278:115–128.
Xu X, Huang J, Li J, Liu L, Han C, Shen Y, et al. (2016). Induced pluripotent stem
cells and Parkinson's disease: modelling and treatment. Cell Prolif
49:14–26.
Yin C-L, Chen HI, Li LH, Chien YL, Liao HM, Chou MC, et al. (2016). Genome-
wide analysis of copy number variations identifies PARK2 as a candidate gene
for autism spectrum disorder. Mol Autism 7:23.
Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, et al.
(2017). SLP-2 interacts with Parkin in mitochondria and prevents mitochon-
drial dysfunction in Parkin-deficient human iPSC-derived neurons and
Drosophila. Hum Mol Genet 26:2412–2425.
Zhang L, Chang S, Li Z, Zhang K, Du Y, Ott J, et al. (2012). ADHDgene: a genetic
database for attention deficit hyperactivity disorder. Nucleic Acids Res
40:1003–1009.
Zhang C, Lee S, Peng Y, Bunker E, Giaime E, Shen J, et al. (2014). PINK1
triggers autocatalytic activation of parkin to specify cell fate decisions. Curr
Biol 24:1854–1865.
Zhu X-R, Maskri L, Herold C, Bader V, Stichel CC, Güntürkün O, et al. (2007).
Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci
26:1902–1911.
Zhu JL, Olsen J, Liew Z, Li J, Niclasen J, Obel C (2014). Parental smoking during
pregnancy and ADHD in children: the Danish National Birth Cohort.
Pediatrics 134:382–388.
Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, Collins AL, et al. (2009).
CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like
mental retardation and determine the level of a common synaptic protein in
Drosophila. Am J Hum Genet 85:655–666.
Cross-species models of ADHD/ASD Dalla Vecchia et al. 17
